Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristy Shafer

Nurse Practitioner, Family Mattoon, IL Nurse Practitioner

NPI 1306314778 CMS profile 10456839

1000 Health Center Dr Ste 107, Mattoon, IL 61938

Open in the dashboard

General payments

$7,842

385 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristy Shafer of Mattoon, IL is reported in the CMS Open Payments database as having received $7,842 across 385 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,602 132
2024 General $2,888 116
2023 General $993 49
2022 General $729 48
2021 General $631 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristy Shafer
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Kristy Shafer were reported at $2,602. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Kristy Shafer Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $631 $124 $35–$379 $132
2022 $729 $141 $44–$430 $149
2023 $993 $154 $49–$476 $160
2024 $2,888 $165 $51–$504 $164
2025 $2,602 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,341 96 payments
  2. Alexion Pharmaceuticals, Inc. $851 10 payments
  3. Mallinckrodt Hospital Products Inc. $516 17 payments
  4. Supernus Pharmaceuticals, Inc. $422 8 payments
  5. Vanda Pharmaceuticals Inc. $389 17 payments
  6. LivaNova USA, Inc. $379 15 payments
  7. Pfizer Inc. $255 20 payments
  8. Biohaven Pharmaceuticals, Inc. $228 20 payments
  9. UCB, Inc. $217 12 payments
  10. Celgene Corporation $194 11 payments
  11. Other $3,051 159 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,943 374 payments
  2. Education $899 11 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $812 62 payments
  2. QULIPTA $693 57 payments
  3. ULTOMIRIS $651 8 payments
  4. ACTHAR $516 17 payments
  5. PONVORY $389 17 payments
  6. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $379 15 payments
  7. BOTOX $277 14 payments
  8. NURTEC ODT Primary Care $262 22 payments
  9. NURTEC ODT Pain $240 19 payments
  10. ZAVZPRET $225 18 payments
  11. Other $3,947 202 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

2,878

Median for Nurse Practitioner: 389

Drug cost

$798,735

Median for Nurse Practitioner: $21,885

Branded share of claims

32.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Briviact Brivaracetam Brand 85 $150,356
Zeposia Ozanimod Hydrochloride Brand 14 $120,801
Aubagio Teriflunomide Brand 12 $108,623
Aptiom Eslicarbazepine Acetate Brand 39 $98,851
Qulipta Atogepant Brand 38 $43,354
Trudhesa Dihydroergotamine Mesylate Brand 12 $37,297
Gocovri Amantadine Hcl Brand 16 $35,342
Ubrelvy Ubrogepant Brand 27 $30,041
Nurtec Odt Rimegepant Sulfate Brand 12 $21,756
Emgality Pen Galcanezumab-Gnlm Brand 30 $21,166

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$61,990

Medicare's payments for the services billed

Medicare patients

298

Average age 72

Services billed

1,478

187 women, 111 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 36%
Depression 35%
Alzheimer's or dementia 33%
Diabetes 28%
Chronic kidney disease 26%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $601
$601 — —
UBRELVY
  • AbbVie, Inc. $177
$177 27 —
Qelbree
  • Supernus Pharmaceuticals, Inc. $156
$156 — —
PONVORY
  • Vanda Pharmaceuticals Inc. $150
$150 — —
QULIPTA
  • AbbVie, Inc. $145
$145 38 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

385 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record